Psychiatria pre prax 4/2024

Transition to LAI aripiprazol (dual-injection start) in a patient with hebephrenic schizophrenia

I am presenting a case study of a 20-year-old man diagnosed with hebephrenic schizophrenia. Since the age of 17, he has been repeatedly hospitalized in various psychiatric facilities due to recurrent relapses, primarily of affective and negative symptoms. For a long time, we were unable to find a suitable antipsychotic medication for the patient, as his symptoms were never adequately controlled and had a significant impact on his daily life. The patient was referred to our outpatient clinic. Despite attempts to adjust his medication, his condition decompensated again, necessitating hospitalization at our clinic. We decided to treat the patient with aripiprazol and transition to a long-acting injectable (LAI) form, combined with olanzapine and a mood stabilizer. We were able to stabilize the patient‘s condition and achieve social recovery.

Keywords: psychosis, hebephrenic schizophrenia, combined antipsychotic therapy, aripiprazole, LAI